No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BMRN240816C100000
- 0.17
- +0.02+13.33%
15min DelayClose Jul 22 16:00 ET
0.17High0.17Low
0.17Open0.15Pre Close1 Volume72 Open Interest100.00Strike Price17.00Turnover35.56%IV17.42%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.0536Delta0.0136Gamma487.49Leverage Ratio-0.0175Theta0.0031Rho26.15Eff Leverage0.0245Vega
Intraday
- 5D
- Daily
News
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor Fitzgerald
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annual return of 14.87%. Currently, Biomarin
Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Meliora Therapeutics ("Meliora"), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter
Comments
Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.
Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness 1
BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.
BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.
1
BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.
Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.
Read more